This suggests that while KRAS drives tumor development, it may not be necessary for maintaining established tumors.185 Specifically, the catalytically active mutation in the PI3K pathway, PIK3CA H1047R, not only provides tumors with a growth advantage but also aids in immune evasion by altering the TME. Here, KRAS is linked to neoplasm.